PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs

Multiple myeloma (MM) is a malignant plasma cell disease with a poor survival, characterized by the accumulation of myeloma cells (MMCs) within the bone marrow. Epigenetic modifications in MM are associated not only with cancer development and progression, but also with drug resistance.

Bibliographic Details

Main Authors:	Herviou, Laurie (Author) , Kassambara, Alboukadel (Author) , Boireau, Stéphanie (Author) , Robert, Nicolas (Author) , Requirand, Guilhem (Author) , Müller-Tidow, Carsten (Author) , Vincent, Laure (Author) , Seckinger, Anja (Author) , Goldschmidt, Hartmut (Author) , Cartron, Guillaume (Author) , Hose, Dirk (Author) , Cavalli, Giacomo (Author) , Moreaux, Jérôme (Author)
Format:	Article (Journal)
Language:	English
Published:	03 October 2018
In:	Clinical epigenetics Year: 2018, Volume: 10, Pages: 1-18
ISSN:	1868-7083
DOI:	10.1186/s13148-018-0554-4
Online Access:	Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s13148-018-0554-4
Author Notes:	Laurie Herviou, Alboukadel Kassambara, Stéphanie Boireau, Nicolas Robert, Guilhem Requirand, Carsten Müller-Tidow, Laure Vincent, Anja Seckinger, Hartmut Goldschmidt, Guillaume Cartron, Dirk Hose, Giacomo Cavalli, Jerome Moreaux